After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is ...

Europe's regulator has recommended Amgen’s biosimilar Humira, paving the way for a cheaper competitor by 2019. Experts from the CHMP scientific committee recommended Amgen’s biosimilar copy ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...